Cytena secures €3M in funding to advance its single-cell technology

By Nikita Chaurasia  | Date: 2019-03-27

Cytena secures €3M in funding to advance its single-cell technology
  • The capital will help to broaden the sales activities of Cytena and capitalize on new applications
  • Single-cells are used in the development of biopharmaceuticals and in stem cell and cancer research

Reports confirm that High-Tech Grunderfonds (HTGF) and two private investors are going to invest another 3 million euros in Cytena GmbH. This capital will be used in developing Cytena’s single-cell printer lab technology, broaden its sales activities and promptly tap into the capabilities of new applications.

Apparently, the two private investors and High-Tech Grunderfonds (HTGF) have confidence in the significance of isolation of single-cell for the development of biopharmaceuticals as well as for genetic analysis in diagnostics and research.

Benjamin Steimle, CFO of Cytena stated that the new capital would help to understand better and serve the customer’s requirements as well as help to increase the market share of the company.

Cytena mentioned that along with way, important milestones achieved include a collaboration in sales with a vital American company and addition of x.sight devices.

In recent years, the analysis of individual biological cells has gained its importance rapidly. These single-cells are used in the development of latest drugs called biopharmaceuticals and also in stem cell and cancer research, the firm said.

Cytena’s single cell printers comprise of laboratory devices for sorting and managing individual viable cells. These instruments are considered as one of the innovative platforms for life science and offer long-term contribution towards the manufacturing and development of new drugs.

According to HTGF Investment Manager, Dr. Lena Krzyzak, investment in the Series A round helps the company to continues its successful growth in start-up financing. Dr. Krzyzak said with the company is greatly confident in its management team’s ability to expand the market and product development.

For the uninitiated, Cytena is a well-known start-up in life sciences which was founded in 2014 at the University of Freiburg, by spinning off from the Institute for Microsystems Technology (IMTEK). The Cytena team has developed the technology called the single-cell printer which enables the isolation of single cells in a gentle, sterile and documented process.

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More >>

More News By Nikita Chaurasia

Swiftly achieves Unicorn status with $100M Series C led by BRV Capital

Swiftly achieves Unicorn status with $100M Series C led by BRV Capital

By Nikita Chaurasia

Swiftly Systems has reportedly achieved unicorn status, securing in funding through a Series C round. The prominent BRV Capital Management led this funding initiative. According to the earlier reports, Swiftly was adopted by hundreds of consumer b...

Rainforest nations unify to demand cash for climate & biodiversity preservation

Rainforest nations unify to demand cash for climate & biodiversity preservation

By Nikita Chaurasia

As per the reports, twelve nations with rainforests united to establish a collective initiative aiming to address climate change and safeguard biodiversity at summit held in Brazil. The declaration, titled "United for Our Forests," emerged ...

AI Chatbot, Llama 2, unveiled by Meta for commercial use via Microsoft

AI Chatbot, Llama 2, unveiled by Meta for commercial use via Microsoft

By Nikita Chaurasia

Meta Platforms has recently introduced Llama 2, an artificial intelligence large language model, for commercial use in collaboration with major cloud providers like Microsoft. Instead of charging for access or usage, Meta aims to share the model with...

Moderna signs agreement to explore mRNA medicines in China

Moderna signs agreement to explore mRNA medicines in China

By Nikita Chaurasia

Moderna Inc, a leading vaccine manufacturer, reportedly announced on Wednesday that it has entered into a memorandum of understanding (MoU) and a land collaboration agreement aimed at exploring opportunities for researching, developing, and producing...

Nike and Epic Games collaborate to launch Airphoria NFT in Fortnite

Nike and Epic Games collaborate to launch Airphoria NFT in Fortnite

By Nikita Chaurasia

The American footwear design & manufacturing company, Nike and Epic Games, the creators of the popular online game Fortnite, have joined forces in an exciting new collaboration. The partnership aims to bring about a groundbreaking change in the d...